澳门威斯尼斯人wns615app-官方入口

0512-62626219

网站首页

关于wns615app

研究领域

研究领域详情

加入wns615app

新闻动态

院内资讯行业新闻

联系wns615app

关于wns615app

澳门威斯尼斯人wns615app（Suzhou Intragrand Pharma）于2019年7月成立于苏州工业园区，是由海外医药专家和行业精英所创立的医药创新公司。

澳门威斯尼斯人wns615app的目标是开发国内外尚缺乏的，在治疗炎症与神经相关等疾病领域市场未满足的小分子药品的差异化策略。

Suzhou Intragrand Pharma founded in Suzhou Industrial Park in July 2019, it is a pharmaceutical innovation company founded by overseas pharmaceutical experts and industry elites. The goal of the company is to explore novel small molecule drugs to meet medical needs in the therapeutic area of inflammation and nerval associated

目前公司领衔研发产品有银屑病、脂溢性皮炎和复发性慢性咳嗽适应症的药物。目前项目在临床enabling阶段。

At present, the company leading the research and development projects are the investigational medicines for psoriasis, Seborrheic Dtrmatitis and Refactory Chronic Cough indications.and the project is currently in the clinical enabling stage.

公司董事长兼总裁朱加望博士，是南京大学本科毕业，在美国卡卢拉多州立大学获得博士学位，纽约州立大学石溪分校从事两年药学博士后研究。朱博士具有包括Amgen, Inc. 和科伦药业等多个国内外上市药物大公司的研发和管理二十多年经验。朱博士于2020年获苏州工业园区第十四届第一批科技创业领军，以及2020年姑苏创业计划。

Dr. Jiawang “Joseph” Zhu, President and CEO of Suzhou Intragrand Pharma, graduated from Nanjing University, obtained his Ph.D. degree from Colorado State University in the United States, and pursued two-year postdoctoral research at State University of New York at Stony Brook. Dr. Zhu has more than 20 years in R&D and management experiences in Biotech and pharmaceutical companies, including Amgen, Inc and Kelun Pharmaceutical. In 2020, Dr. Zhu won the scientific and technological entrepreneurship leaders in the 14 th Suzhou Industrial Park and the Gusu Entrepreneurship Plan in 2020.